From Validation to Deployment: Why Medical AI Fails to Reach Sustained Clinical Use

Medical artificial intelligence exhibits a recurring pattern: systems that perform well in validation studies frequently fail to achieve sustained clinical use. The limiting factor is rarely the algorithm. It is the set of requirements that lie between a validated model and a functioning tool at the point of care. A number of institutions have expended in excess of one million dollars on AI sepsis prediction systems that reported sensitivity of 89% or higher on validation, and many of those systems are now effectively inactive within the electronic health record, generating alerts that are dismissed and dashboards that are not consulted.

This is not a problem of algorithm quality. It is a problem of deployment, that is, of the work required to fit an AI system into a clinical environment alongside existing workflows, institutional practice, and the manner in which clinicians actually make decisions. In this article, we characterize the gap between validation and deployment, which we regard as among the most consequential and least examined problems in medical AI.

Reported Performance and Observed Implementation

The volume of medical AI research has increased substantially over the past decade. PubMed indexes a growing number of validation studies reporting areas under the receiver operating characteristic curve above 0.95 and sensitivity and specificity comparable to or exceeding those of human readers, across nearly every specialty. Implementation has not increased proportionally.

Publication is not implementation, and accuracy on a curated research dataset is weakly informative regarding utility in clinical practice. A model that performs well on a curated cohort frequently degrades on the incomplete and noisy data characteristic of routine practice. Moreover, the objectives differ: research optimizes a single criterion, typically discrimination, whereas deployment must simultaneously satisfy usability, integration, clinician trust, and latency constraints, none of which are represented in a confusion matrix. This mismatch of objectives, rather than any deficiency in model accuracy, constitutes the principal barrier.

Modes of Deployment Failure

Technically sound algorithms fail in deployment because performance in validation and performance in clinical use are distinct claims. The discrepancy arises along several independent dimensions, any one of which is sufficient to prevent adoption of an accurate model. The five most frequently observed are described below.

1. Workflow Mismatch

Workflow mismatch is the most common failure mode and occurs whenever a system is designed without reference to the temporal structure of clinical work. Consider a sepsis model that re-evaluates and issues an alert every 15 minutes as new vital signs and laboratory results become available. In a research setting this behavior is desirable, as it provides the most current risk estimate. In clinical practice, a physician may be responsible for 30 patients while conducting a goals-of-care discussion, performing a procedure, and responding to pages. An alert issued during a family discussion is not observed. It reappears during documentation and is dismissed to preserve continuity of thought. Before it can be reviewed, another page redirects attention, and it is dismissed again. Within a short period, the physician has been conditioned by repetition to dismiss every alert from that system without reading it.

The design error is that the system was added to the workflow as an additional demand on attention rather than incorporated into it. Correct design requires knowledge not only of which decisions clinicians make but of when those decisions are made, what information is being reviewed at that time, what else is competing for attention, and where support can be delivered without increasing load. An alert delivered at an inappropriate time increases rather than reduces cognitive burden, and clinicians respond rationally by minimizing that burden, including by disregarding information that would have been useful.

2. Inadequate EHR Integration

The second failure mode is absent or partial integration, in which the AI system operates outside the applications in which clinical work is performed. Consider a radiology tool that requires the radiologist to exit the PACS viewer during interpretation, authenticate to a separate vendor portal, upload the study manually, wait approximately 90 seconds, and transcribe the result into the report. Each step introduces friction in the form of a context switch, a delay, and an opportunity for error or abandonment. Irrespective of accuracy, such a tool is not usable by a radiologist interpreting a high volume of studies per day.

Friction is a principal determinant of adoption. Each additional click, authentication step, or context switch constitutes a reason not to use the tool, and a clinician operating under time pressure will not routinely transfer to a separate application regardless of the tool's accuracy. This should not be characterized as resistance to technology; it is a rational allocation of limited time. Integration is therefore a precondition rather than a feature. The system must operate within the applications in which the work already occurs, presenting results in context rather than requiring a detour.

3. Latency and Infrastructure

The third failure mode is latency, which is frequently underweighted during algorithm development. A prediction returned in 45 seconds is acceptable for retrospective research. It is not acceptable when the decision concerns intubation in respiratory failure or activation of a stroke protocol. Clinical decisions occur in real time, and a system that cannot return a result within the relevant interval is not used. When the alternatives are to wait for the model or to act on clinical judgment, clinicians act, because deferring a necessary intervention is not acceptable.

Mitigation involves both faster inference and anticipatory scheduling: predicting which outputs a clinician will require from the current patient context and computing them in advance, during intervals when the system is otherwise idle, so that the result is available when requested. A proportion of such pre-computed predictions will not be used, but the associated compute cost is small relative to the cost of clinician time or of an abandoned deployment. A model that cannot operate at the pace of the work will not be used irrespective of its accuracy.

4. Cognitive Load and Alert Fatigue

Alert fatigue arises from the interaction between finite clinician attention and an increasing volume of automated alerts. Physicians dismiss approximately 90% of electronic health record alerts, having learned that most are not informative: drug interaction warnings triggered by routine orders, prompts to order tests already ordered, and laboratory flags for values that are within the individual patient's established range. An additional AI-generated alert introduced into this environment, for example a sepsis warning on a clinically stable patient with an uncomplicated urinary tract infection, increases the noise rather than the signal.

Each alert, irrespective of the sophistication of the model producing it, increases the probability that the next alert is dismissed. This is habituation acquired over a large number of repetitions rather than inattention, and careful evaluation of every alert would not be compatible with the clinical workload. Adding alerts to a saturated environment does not improve decisions. The relevant objective is not alert volume but signal-to-noise ratio: an AI notification must have a positive predictive value sufficient for clinicians to treat it as informative.

5. Practice Variation and Consistency

Practice variation is a persistent quality and safety problem that AI deployment both reveals and may partially address. Most physicians believe they adhere to guidelines and practice similarly to their colleagues, since the alternative implies that some component of their practice is suboptimal. In fact, individual approaches develop from training, local practice culture, and experience, and the resulting differences produce variability in care and ambiguity within teams. Professional societies invest substantially in evidence-based care pathways, but adherence is variable, sometimes reflecting deliberate clinical judgment and more frequently reflecting unawareness or the absence of any systematic prompt. Other high-reliability industries have addressed analogous problems with standardized process modeling, of which BPMN is one example; healthcare has adopted such methods to a considerably lesser extent. Embedding evidence-based pathways in the workflow, rather than relying on individual recall, is one mechanism by which AI-supported systems may reduce this variation.

Human Factors

Beyond the technical barriers, deployments fail when human factors are not addressed, specifically how clinicians reason, decide, and interact with decision support. These factors determine whether a system is used as intended or circumvented.

Trust Calibration

Trust in an AI system is not binary. Clinical use requires calibrated trust, that is, the ability to determine when a recommendation should be relied upon and when it should be overridden on the basis of context unavailable to the model. Such calibration requires that the system provide sufficient information for case-level judgment. Most deployed systems do not. They return a prediction without a confidence estimate, without an explanation, and without indication of which features contributed. The clinician must therefore decide whether to act on the model without any basis for determining whether the case falls within the region in which the model performs reliably.

The result is persistent uncertainty regarding whether a given alert should be followed, and in the absence of case-level information, clinicians adopt blanket policies of acceptance or rejection. A common misconception compounds this. The numerical output of a classification model is frequently interpreted as a probability or a confidence estimate. It generally is not. The value produced by a network's final softmax layer is optimized to minimize a training loss rather than to report a calibrated probability. Such outputs can be calibrated to yield probabilities, but this requires additional procedures that deployed systems frequently omit. Clinicians do not require that a model be infallible, any more than they require this of a human consultant, but they do require that it represent its uncertainty accurately.

Responsibility for Erroneous Output

The allocation of responsibility when a model is incorrect affects clinician willingness to use these systems. Consider a system that classifies a patient as low risk, on which basis the physician withholds aggressive intervention, and the patient subsequently deteriorates. The algorithm cannot be held accountable, as it possesses neither agency nor legal standing. The vendor typically disclaims responsibility in the license terms. The physician may carry no strict legal liability in jurisdictions that treat reliance on validated decision support as reasonable, but the clinical and personal consequences remain: the discussion with the patient and family, the management of the complication, and the professional consequences of a missed diagnosis.

Clinicians recognize this asymmetry and act accordingly. Where a system does not explain the basis for a recommendation, the rational response is to rely on independent judgment, which avoids accountability for a decision that cannot be justified. Deployments that do not address this consideration are unlikely to succeed. A tool that provides no transparency, no explanation, and no accurate representation of its uncertainty transfers liability to the clinician without a corresponding benefit. Systems intended for clinical use should therefore support decisions the clinician can articulate and defend rather than issue determinations that must be either accepted or rejected without basis.

Catastrophic Failure Modes

The potential for severe errors is not theoretical, and regulatory clearance does not by itself protect against it.⁵ Consider an illustrative scenario in which an FDA-cleared system for intracranial imaging classifies a meningioma as an intracranial hemorrhage. These diagnoses require opposite management, and the error could result either in unnecessary neurosurgical intervention or in a missed treatable tumor. Such a failure may occur after an algorithm has satisfied validation criteria and obtained clearance, in that the system meets the statistical performance thresholds required for approval on its validation dataset while producing an incorrect output on an atypical case encountered in practice.

The general point is that a model fitted to its training and validation distributions may fail unpredictably on edge cases, atypical presentations, or pathology that was sparsely represented. No validation process, whether conducted by investigators or by regulators, can evaluate every clinical scenario, and models may be brittle, in that a small departure from the training distribution produces a confidently incorrect output. Without clinician oversight and an accessible mechanism for detecting and overriding such errors, these systems may cause harm. Safe deployment therefore requires error detection, defined override pathways, and ongoing monitoring capable of identifying failure modes not represented in validation.

Characteristics of Successful Deployment

Failure is common but not inevitable. Systems that achieve sustained adoption share identifiable design characteristics, and notably these concern deployment strategy and workflow integration rather than algorithmic sophistication. The principles described below distinguish tools that achieve sustained use from those that are abandoned.

Integration Rather Than Addition

Effective tools operate within the workflow rather than alongside it, requiring no additional authentication, no separate application, and no navigation to a separate interface; the output appears in the interface the clinician is already using. Consider a system that proposes differential diagnoses within the electronic health record progress note as the clinician documents symptoms and examination findings. The clinician is not using an AI tool as a discrete activity; the suggestions appear alongside the note and may be reviewed, accepted, or disregarded without interruption.

This constitutes frictionless integration, in which the model functions as ambient support rather than as a separate task. Because access requires no additional effort, adoption depends only on whether the output is useful. The general principle is to make existing work easier without making it different. Tools designed on this principle tend to be adopted and retained.

Defined Ownership and Escalation Pathways

Accurate prediction is not sufficient; a deployment must also specify the subsequent action. When the system identifies a problem, several questions require answers determined in advance: who responds, what action is taken, within what interval, and what information is required. Where the answer is that the clinician determines this individually, the deployment is likely to fail, since the translation from prediction to action is assigned to a clinician who may lack the time, resources, or authority to act. An AI system should initiate a structured workflow rather than only identify a problem.

Training in Interpretation Rather Than Compliance

The objective is not compliance but an informed combination of clinical judgment and model output, and this requires training that effective deployments incorporate. Clinicians require four categories of information. First, what the model learned, comprising the populations on which it was trained, how outcomes were labeled, and which features contribute to predictions. Second, when the model should be relied upon and when it should be treated with caution, including how performance varies across demographic subgroups, disease severities, and presentations. Third, how to combine model output with clinical judgment, neither disregarding it by default nor accepting it uncritically. Fourth, explicit authorization to override the model where the clinical context warrants, together with the documentation required for medicolegal and quality assurance purposes.

Clinicians who understand a system's operating characteristics use it more effectively than those who treat it as opaque. With an accurate model of how the algorithm behaves, they can determine when its output applies, identify cases warranting override, and integrate its suggestions with other information. Training that establishes this understanding is a component of deployment rather than an optional supplement.

Continuous Monitoring and Feedback

Deployment is not a discrete event. It is a continuing process comprising surveillance of real-world performance, structured collection of clinician feedback, early identification of failure modes, and iterative improvement of both model and integration. Effective deployments monitor several quantities concurrently. They record how frequently clinicians override the model and why, examining override patterns for evidence of systematic limitation. They assess whether predictions correspond to observed patient outcomes on follow-up, which identifies drift. They record which alerts result in action and which are dismissed, distinguishing informative output from alert-fatigue contributors. They assess clinician trust over time, to determine whether confidence is increasing or decreasing.

Monitoring is what makes adaptation possible. Drift is expected, since populations change, practice evolves, and data quality varies, and a monitored system identifies degradation early enough to permit a response through retraining, workflow modification, or adjustment of the tool. An unmonitored system degrades without detection until the discrepancy between expected and observed performance is sufficient for clinicians to abandon it, frequently without the cause being identified. This distinction separates systems that improve over time from systems that degrade until they are withdrawn.

Implications for Clinicians

For students, residents, and early-career physicians, these considerations become more consequential as AI tools are more widely deployed. Adoption will be requested. Some tools will improve decisions and patient care; many will not. The capacity to evaluate a tool critically, before investing the effort required to learn it, is becoming a core competency, and understanding deployment is what permits systems likely to achieve sustained use to be distinguished from those likely to be abandoned.

Regulatory Clearance and Clinical Success

It is frequently assumed that an FDA-cleared tool has been comprehensively evaluated and is ready for clinical use. This misinterprets what clearance establishes. For AI-based Software as a Medical Device, the FDA principally evaluates safety and effectiveness in controlled settings against predefined datasets. It does not evaluate real-world usability, workflow integration, sustained adoption, or performance stability as populations and practice change.⁵ Most medical AI is cleared through the 510(k) pathway, which requires demonstration of substantial equivalence to an existing predicate device. This establishes a baseline of safety and effectiveness but does not require a prospective trial demonstrating improved outcomes, satisfactory workflow integration, or durable real-world use.

A cleared tool may therefore fail in deployment if it introduces workflow friction, contributes to alert fatigue, does not achieve clinician trust, or degrades on patients who differ from its training population. Clearance is a necessary condition and a floor on safety and effectiveness under specified conditions. It is not sufficient for clinical success, which depends on the deployment factors described above. When evaluating a tool, attention should be directed beyond regulatory status to the factors that predict use: workflow integration, latency, explainability, monitoring plan, and evidence of sustained use at comparable institutions.

Questions to Ask Before Adoption

Evaluation should extend beyond the reported accuracy to the factors that predict use. Six questions are recommended:

• Workflow integration: where does the system fit within the existing workflow? An answer involving a separate portal, a distinct system, or manual data transfer predicts friction and limited adoption.
• Latency: what is the time to return a result? If it exceeds the interval available for the decision it supports, the system will not be used, since care cannot be deferred to await it.
• Error detection: how would a clinician determine that the output is incorrect? Inability to answer this question indicates that oversight has not been addressed in the design.
• Evidence of sustained use: which institutions are using the system, and with what result? Reference sites should be requested and the clinicians at those sites contacted. Procurement without sustained use is informative.
• Population correspondence: does the training population resemble the local patient population with respect to demographics, disease prevalence, and severity? Substantial divergence predicts degraded performance.
• Override: what is required to override the system? Where override is difficult, obscured, or requires extensive justification, clinicians will disregard the system entirely.

The Role of Early Clinician Involvement

One principle distinguishes tools that succeed from those that do not: effective systems are designed with clinicians rather than for them by developers without direct knowledge of the work. Early and sustained clinician involvement in both development and procurement is a determinant of success. Three practices are recommended for clinicians participating in either process. First, map the workflow before development, including the actual sequence of steps, the information consulted, the timing of decisions, and the points at which support would be useful or would interfere. Second, evaluate iteratively with real users in operational settings rather than retrospectively on historical data; piloting with structured feedback identifies friction, usability, and trust problems before substantial resources have been committed. Third, monitor the metrics that track deployment success, including alert acceptance rate, time to action, and user satisfaction, rather than sensitivity and specificity alone.

The contrast is substantial. Systems developed without reference to clinical practice, optimized for metrics that are persuasive in review but not consequential at the point of care, fail in deployment. Systems developed with clinician participation and refined through feedback on actual use are considerably more likely to be adopted and to produce measurable benefit. Clinician involvement is therefore a technical requirement rather than a stakeholder management activity.

---

Conclusion

The dominant failure mode in medical AI is failed deployment rather than inadequate algorithms. Most systems do not achieve sustained clinical use, and in most cases this is not attributable to insufficient accuracy. Deployment is more difficult than model development, than validation study design, and than publication, and the obstacles are organizational, workflow-related, and human rather than mathematical. Many deployments additionally depend on rigid, hard-coded integrations that become costly to modify when a workflow changes or a model requires updating, and this brittleness contributes to abandonment even following a successful initial implementation.

Constructing an accurate model is largely a technical problem, addressable with data, compute, and appropriate methods. Deploying it is not. Deployment requires an accurate understanding of how clinicians work and decide, management of organizational change, clinician trust established through transparency and reliability, and a design consistent with the interruption-driven reality of clinical practice rather than with an idealized process diagram. These are different competencies from model development, and the associated effort is consistently underestimated.

When a vendor presentation emphasizes an AUC of 0.95 or comparable discrimination metrics, the appropriate response is to redirect the discussion toward deployment. Specifically, how the system integrates into existing electronic health record workflows and whether integration requires workflow redesign; what occurs when the system produces an erroneous prediction and how clinicians detect and correct such errors; and which institutions are using the system successfully, with direct contact requested to confirm sustained use rather than procurement alone. These questions are considerably more informative regarding likely success than accuracy metrics.

The relevant test of a medical AI system is therefore not the performance reported in a validation study. It is whether clinicians continue to use the system at six, twelve, and twenty-four months following deployment, and whether that sustained use is associated with measurable improvement in clinical efficiency, decision quality, or patient outcomes. This longer-term criterion should inform both development priorities and procurement decisions.

---

References & Further Reading

1. Sendak MP, Gao M, Brajer N, Balu S. A Path for Translation of Machine Learning Products into Healthcare Delivery. NEJM Catalyst Innovations in Care Delivery. 2020. https://catalyst.nejm.org/doi/full/10.1056/CAT.19.1084
2. Topol EJ. Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again. Basic Books; 2019.
3. Rajkomar A, Dean J, Kohane I. Machine Learning in Medicine. N Engl J Med. 2019;380(14):1347-1358. doi:10.1056/NEJMra1814259
4. Shortliffe EH, Sepúlveda MJ. Clinical Decision Support in the Era of Artificial Intelligence. JAMA. 2018;320(21):2199-2200. doi:10.1001/jama.2018.17163
5. Zhang Y, Saini N, Janus S, Swenson DW, Cheng T, Erickson BJ. United States Food and Drug Administration Review Process and Key Challenges for Radiologic Artificial Intelligence. J Am Coll Radiol. 2024;21(6):920-929. doi:10.1016/j.jacr.2024.02.018
6. Erickson BJ, Kitamura F. Artificial Intelligence in Radiology: a Primer for Radiologists. Radiol Clin North Am. 2021;59(6):991-1003. doi:10.1016/j.rcl.2021.07.004
7. Rouzrokh P, Wyles CC, Philbrick KA, Ramazanian T, Weston AD, Cai JC, Taunton MJ, Kremers WK, Lewallen DG, Erickson BJ. Part 1: Mitigating Bias in Machine Learning—Data Handling. J Arthroplasty. 2022;37(6S):S406-S413. doi:10.1016/j.arth.2022.02.092
8. Zhang Y, Wyles CC, Makhni MC, Maradit Kremers H, Sellon JL, Erickson BJ. Part 2: Mitigating Bias in Machine Learning—Model Development. J Arthroplasty. 2022;37(6S):S414-S420. doi:10.1016/j.arth.2022.02.085